Loading clinical trials...

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients | Clinical Trials | Clareo Health

Not Yet RecruitingPhase 3NCT07056478

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in ...

Lead sponsor: Prince of Wales Hospital, Shatin, Hong Kong•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Ronald Man Yeung Wong

CONTACT

852 3505 1654 ronald.wong@cuhk.edu.hk

Related studies

RECRUITINGNA

Effect of Micronized Creatine Monohydrate on Muscle Mass, Strength and Performance in Older Adults Submitted to Total Knee Arthroplasty

NCT06925880 · Sarcopenia in Elderly, Frailty at Older Adults, and more

RECRUITINGNA

Evaluation of the JUICE HA® as an Anti-sarcopenia

NCT06950125 · Sarcopenia in Elderly

RECRUITING

Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer Diagnosis Taken to Curative Resectable Surgery

NCT07412379 · Cancer Abdomen, Elderly (People Aged 65 or More), and more

RECRUITINGPhase 2

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

NCT06811324 · Obesity Prevention, Sarcopenia in Elderly, and more

RECRUITINGNA

The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population

NCT07322653 · Sarcopenia in Elderly, Malnourished, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 9, 2025Terms

Trial snapshot

StatusNOT_YET_RECRUITING

PhasePHASE3

Enrollment130

Start dateJan 2026

Last updatedJul 9, 2025

Condition

Sarcopenia in Elderly

Locations shown

The Chinese University of Hong Kong

Hong Kong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 9, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Contacts

Sponsors

Related studies

Effect of Micronized Creatine Monohydrate on Muscle Mass, Strength and Performance in Older Adults Submitted to Total Knee Arthroplasty

Evaluation of the JUICE HA® as an Anti-sarcopenia

Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer Diagnosis Taken to Curative Resectable Surgery

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population

Trial snapshot

Condition

Locations shown

For caregivers